Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ILOTYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN STEARATE versus ILOTYCIN.
ERYTHROCIN STEARATE vs ILOTYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking the translocation step. It may also act as a motilin receptor agonist, stimulating gastrointestinal motility.
Erythromycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking peptidyl transferase activity and preventing translocation of peptides.
250-500 mg orally every 6 hours for mild to moderate infections; up to 4 g/day for severe infections.
Erythromycin base (Ilotycin): 250 mg orally every 6 hours or 500 mg every 12 hours; maximum 4 g/day. For IV: 15-20 mg/kg/day continuous infusion or divided every 6 hours.
None Documented
None Documented
1.5-2 hours in adults; prolonged to 5-6 hours in severe hepatic impairment. In anuria, half-life not significantly affected.
Terminal elimination half-life is 1.5-2 hours in adults, prolonged to 4-6 hours in severe renal impairment (CrCl <10 mL/min), requiring dose adjustment.
Primarily biliary-fecal (90-95% as unchanged drug and metabolites); renal excretion accounts for 2-15%.
Approximately 80-90% renal excretion as unchanged drug via glomerular filtration and tubular secretion; 10-15% biliary/fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic